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Summary Intratumoral induction of tumour necrosis factor (TNF) by administration of Bordetella pertussis
vaccine (BPV) as compared with that by the agent OK-432 was investigated in mice. Two hours after such
administration tumour tissues tested were resected from the mice, homogenised, and the TNF activities in the
homogenate were assayed using a L-929 fibroblast assay. Intravenous injection of BPV into mice bearing the
MM46 carcinoma resulted in a greater concentration of TNF in the tumour homogenate than in the serum.
With OK-432, however, there was a greater concentration of TNF in the serum than in the tumour
homogenates. A high level of intratumoral TNF induction by BPV was also observed in mice bearing Meth A
fibrosarcoma or Lewis lung carcinoma. The therapeutic effect against the Meth A fibrosarcoma was in parallel
with the intratumoral TNF activity. Intratumoral TNF activity is therefore believed to be a good index of
therapeutic effect.
In 1975, Carswell et al. reported that the sera of endotoxin
(LPS)-treated animals infected with Bacillus Calmette-Gu&rin
(BCG) caused haemorrhagic necrosis of various tumours in
mice without apparent side-effects in the host (Carswell et al.,
1975). The factor responsible for this activity in the serum
was called tumour necrosis factor (TNF). TNF can be effect-
ively induced by two-stage stimulation, priming with BCG
and triggering with LPS. Both agents are derived from bac-
terial bodies. In previous studies we developed an experi-
mental model for endogenous production of TNF which is
clinically applicable, because various commercial prepara-
tions of biological response modifiers (BRM), mainly of
bacterial origin, could be used as primers or triggers (Satoh
et al., 1986a,b,c; Minagawa et al., 1987, 1988). With a com-
bination of purified protein derivative (PPD) plus OK-432
(bacterial body of Streptococcus sp.) or IFN-y plus OK-432
we achieved partial regression of lung and liver tumours in
patients (Kato et al., 1985, 1987). These clinical trials are in
progress. A brief review of our work to date has been
published (Soma et al., 1990). With time, problems encount-
ered in treating patients have led to recognition of the
desirability of using a single agent in a simpler procedure in
clinical trials.
In a previous paper, we reported that systemic administra-
tion of Bordetella pertussis vaccine (BPV) induced high TNF
activity in the sera of mice when MAF or IFN-' was used as
a primer (Minagawa et al., 1988). With localised injection
into tumour tissue, a single injection of BPV could induce
intratumoral TNF activity.
In this paper, we report that BPV can also induce high
intratumoral TNF activity when administered as a single
systemic injection.
Materials and methods
Animals
Male C3H/He, female BALB/c and C57BL/6 mice, 4-7
weeks old, were purchased from Shizuoka Experimental
Animal Farm (Shizuoka, Japan).
Cell line
A transformed cell line (L-929) originally derived from a
C3H/He strain mouse was grown in Eagle's minimum essen-
tial medium (MEM; Nissui Seiyaku Co., Tokyo, Japan)
supplemented with 5% fetal calf serum (FCS; Hyclone Lab-
oratories, USA) and was passaged every 3 or 4 days.
Chemical reagents
BPV which contained approximately 2 x 10'0 killed bacteria
in 1 ml of saline was obtained from Chiba Serum Institute
(Chiba, Japan) and OK-432, penicillin- and heat-treated lyo-
philised powder of Streptococcus pyogenes (Uchida et al.,
1980) was from Chugai Seiyaku Co. (Tokyo, Japan).
Rabbit anti-murine TNF-a antiserum (anti-MuTNF Ab)
was purchased from Genzyme (Boston, USA) and a mono-
clonal antibody against mouse macrophage (anti-macrophage
Ab) was from Sera-Lab. (Sussex, UK). Recombinant murine
interferon-y (Mu-IFN-'y) was kindly provided by Toray
Industries Inc. (Tokyo, Japan).
TNF assay
TNF activity of test samples was assayed using L-929 mouse
fibroblasts in the presence of actinomycin D (1 ig ml-') by
the method of Ruff and Gifford (1980) with minor modifi-
cations (Gatanga et al., 1985, 1989) involving the extrapola-
tion assay (Treffers, 1956). Units of activity were calculated
as the dilution factor of serum allowing survival of half the
L-929 cells with rTNF-a (PAC-4D; 2 x 106 units mg-', do-
nated by Asahi Chemical Ind., Tokyo, Japan) as an internal
reference in each assay, in order to avoid possible fluctuation
due to culture conditions.
Inoculation of tumour cells
For TNF assay, MM46 carcinoma and Meth A fibrosarcoma
cells (1 x 106 cells) were inoculated intradermally (i.d.) into
the abdominal region of C3H/He and BALB/c mice, respec-
tively. Lewis lung (3LL) carcinoma cells (3 x 105 cells) were
inoculated subcutaneously (s.c.) into the inguinal region of
C57BL/6 mice. For the test of therapeutic response, Meth A
fibrosarcoma cells (4 x 106 cells) were inoculated s.c. into the
inguinal region of BALB/c mice.
Injection ofinducers
In the case of i.v. or per os (p.o.) injection, mice were treated
with 4 x 109 cells of BPV or 3 Klinishe Einheit (1 KE corre-
sponding to 1 x 101 cells of killed Streptococcus pyogenes) of
OK-432. In the case of intratumoral (i.t.) injection, mice were
treated with 2 x 109 cells of BPV or 1.5 KE of OK-432.
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Serum and intratumoral TNFactivity
On day 9 (MM46 and 3LL) or on day 16 (Meth A) after
tumour inoculation, mice were injected with inducers. Sera
and tumours were removed 2 h after this injection. The
tumours were removed after exsanguination of the mice. A
5% homogenate of tumour in saline was centrifuged at
3,000 r.p.m. for 10 min and supernatant was taken for TNF
assay.
Therapeutic test
On day 9 or on days 9 and 16 after tumour inoculation, BPV
or OK-432 was injected i.v. into Meth A-bearing mice (11 or
15 weeks old). At intervals the largest and smallest diameters
of each tumour were measured with a slide caliper and the
average diameter (mm) was recorded.
Neutralisation ofintratumoral TNFactivity by anti-MuTNF Ab
In a 96-well flat-bottomed microtitre plate, 5% of tumour
homogenate and anti-MuTNF Ab (final concentration; 103
neutralising units per ml) were mixed in 0.2ml of MEM
supplemented with 5% FCS. After 3 h incubation at 37°C, an
aliquot of the medium was tested in the TNF assay.
Neutralisation ofintraperitoneal TNFactivity inducedby the
injection ofMM46 carcinoma cells and BPV
C3H/He mice were treated i.v. or intraperitoneally (i.p.) with
0.2 ml of anti-macrophage Ab. Two hours later mice were
treated i.p. with 5 x 106 MM46 tumour cells. The next day
4 x 109 cells of BPV were administered i.p. and a further
2 h later, the peritoneal fluid was washed out with 3 ml of
Hank's solution for TNF assay.
Effect ofMu-IFN-y on serum and intratumoral TNF induction
On day 9 after MM46 tumour inoculation, 104 units of
Mu-IFN-,y were injected i.v. Three hours later 4 x 109 cells of
BPV were injected i.v. and, after a further 2 h, sera and
tumours were obtained for TNF assay.
Results
Effect ofroute ofadministration ofinducers on endogenous
TNF induction
MM46-bearing mice, 11 weeks old, were administered with
inducers by various routes. Serum and intratumoral TNF
activities after this administration are shown in Table I. By
i.t. injection, both BPV and OK-432 induced high intra-
tumoral TNF activities; the values were 40 and 20 unitsg-',
respectively. By i.v. route, BPV could induce high intra-
tumoral TNF activity (32 units g '), whereas OK-432 did not
induce any detectable activity. However, OK-432 induced
higher serum TNF activity than did BPV. In the p.o. route,
TNF activity could not be detected by either inducer.
Endogenous TNF induction in Meth A or 3LL-bearing mice by
i.v. administration
Serum and intratumoral TNF activities after i.v. injection of
inducers in Meth A or 3LL-bearing mice (10 or 13 weeks
old) are shown in Table II. BPV induced about 40 and 50
times higher intratumoral TNF activities than OK-432 in
3LL and Meth A-bearing mice. On the other hand, higher
serum TNF activities were induced by OK-432 2 h after i.v.
injection.
Time course ofchange in intratumoral TNFactivity
On day 9 after the inoculation of MM46 tumour cells,
4 x 109 cells of BPV and 3 KE of OK-432 were injected i.v.
The change of intratumoral TNF activity with time after the
Table I Effect of route ofadministration ofinducers on endogenous
TNF production
Relative TNFactivity
Inducer Treatment Serum (unitml') Tumour (unitg-')
BPV i.t. n.d. 40.0±0.17
i.v. 0.55±0.83 32.0±0.02
p.o. n.d. n.d.
OK-432 i.t. n.d. 20.0±0.04
i.v. 4.40±0.02 n.d.
p.o. n.d. n.d.
n.d. = not detected. On day 9 after intradermal tumour inoculation
(1 x 106 MM46 tumour cells per mouse), inducers were administered.
By the i.v. or p.o. route, mice were treated with 4 x 109cells ofBPV or
3 KEofOK-432. Bythei.t. route, miceweretreatedwith2 x I09cellsof
BPV or 1.5 KEofOK-432. At 2 h afteradministration ofinducers, sera
and tumours of the 3 animals were resected for measurement ofTNF
activity.
Table II Endogenous TNF induction in Meth A or 3 LL-bearing
mice
Relative TNFactivity
Inducer Tumour Serum (unitmlt') Tumour (unitg-')
BPV Meth A n.d. 31.4±0.33
3 LL 0.20±0.60 28.0±0.16
OK-432 Meth A 10.1 ±0.01 0.60±0.77
3 LL 1.17±0.15 0.70±0.00
n.d. = not detected. Mice wereinoculated intradermally with 1 x 106
cells of Meth A fibrosarcoma or s.c. with 3 x 105 cells of Lewis lung
carcinoma. On day 16 (Meth A) or on day 9 (3 LL) after the tumour
inoculation, micewereinjected i.v. with4 x I09cellsofBPV. Twohours
later tumours ofthe 3 animals were resected for measurement ofTNF
activity.
injection is shown in Figure 1. The intratumoral TNF
activity reached a maximum (22 units g- ) 1 h after BPV
injection and then decreased, becoming negligible after 6 h.
On the other hand, intratumoral TNF activity was barely
detected at any time following OK-432 injection.
Therapeutic test
The therapeutic effect of i.v. injection of BPV or OK-432 was
investigated. The tumour diameters were measured at inter-
vals following tumour inoculation. The result of BPV injec-
tion against Meth A fibrosarcoma is shown in Figure 2 and
that of OK-432 in Figure 3. BPV was more effective than
OK-432 in the case of both single and multiple injection.
Complete cure was achieved in 16.7% and 33.3% of mice by
single and multiple injections of BPV respectively.
Neutralisation ofintratumoral TNFactivity by anti-MuTNF Ab
Neutralisation of intratumoral TNF activity in MM46 and
Meth A-bearing mice by anti-MuTNF Ab is shown in Table
III. In both cases, intratumoral TNF activities were com-
pletely neutralised with anti-MuTNF Ab.
Decrease in intraperitoneal TNF activity induced by the
injection ofMM46 carcinoma cells and BPV by anti-
macrophage antibody
Decrease in intraperitoneal TNF activity by anti-macrophage
Ab which recognises a Mac-I antigen on mononuclear
phagocytes (Springer et al., 1979) is shown in Table IV. TNF
activity was induced in the peritoneal fluid by the i.p. injec-
tion of MM46 tumour cells and BPV. TNF activity was
reduced more than 90% by pretreatment with anti-macro-
phage Ab.374 H. MINAGAWA et al.
Effect ofMu-IFN-y on serum and intratumoral TNFinduction
Effect of Mu-IFN-'y on serum and intratumoral TNF induc-
tion in MM46-bearing mice is shown in Table V. In serum,
about a hundred-fold increase in TNF activity was observed
with Mu-IFN-y, while only 40% increase was observed intra-
tumorally with this BRM.
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Figure 1 Time course of change in intratumoral TNF activity.
On day 9 after the intradermal inoculation of I x 106 MM46
tumour cells, 3 mice were injected i.v. with 4 x 10' cells of BPV
and 3 KE of OK-432. Intratumoral TNF activity with time after
injection of inducers was measured. 0, BPV; 0, OK-432 treat-
ment.
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Figure 2 Systemic therapy with BPV against Meth A fibrosar-
coma. Six BALB/c mice received subcutaneously inocula of
4 x 106 cells of Meth A fibrosarcoma on day 0. On day 9 or on
days 9 and 16, they were treated i.v. with 4 x 10' cells of BPV.
0, control; 0, day 9 treatment (data are for 5 mice; I mouse in
which complete tumour regression occurred is excluded); A, days
9 and 16 treatment (data are for 4 mice; 2 mice in which
complete tumour regression occurred are excluded). Significantly
different from the control: *P<0.01, **P<0.001.
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Figure 3 Systemic therapy with OK-432 against Meth A
fibrosarcoma. Six BALB/c mice received subcutaneously inocula
of 4 x 10' cells of Meth A fibrosarcoma on day 0. On day 9 or
on days 9 and 16, they were treated i.v. with 3 KE of OK-432.
*, control; 0, day 9 treatment; A, days 9 and 16 treatment.
Significantly different from control: *P<0.05.
Table III Neutralisation of intratumoral TNF activity by anti-
MuTNF Ab
Tumour Anti-MuTNFAb TNFactivity (unitg-')
MM46 12.0±0.02
+ n.d.
Meth A 48.0±0.02
+ n.d.
n.d. = not detected. A 5% of tumour homogenate obtained from 3
mice and anti-MuTNF Ab (103 neutralising units ml-') were incubated
at 37C for 3 h and the TNF activities were measured.
Table IV Neutralisation by anti-macrophage Ab of intraperitoneal
TNF activity induced by the injection of MM46 carcinoma cells and
BPV
Anti-macrophage MM46 tumour cells BPV TNFactivity
Ab (5 x 10' cells) (4 x 10' cells) (unit ml-)
- - + 3.8±0.0
+ + 35.8±0.1
+ (i.v.) + + 2.6±0.2
+ (ip) + + n.d.
n.d. = not detected. Mice were treated with anti-macrophage-Ab
(Sera-Lab.) and2 hlatertreatedwith MM46tumourcells. Thenextday
BPV was injected and 2 h later peritoneal fluid was obtained from 3
animals for measurement of TNF.
Table V Effect of Mu-IFN-y on serum and intratumoral TNF
induction
Mu-IFN-'y
Inducer - +
Serum (unit ml-') BPV 1.6±0.2 170±0.3
Tumour (unit g ') BPV 46.7±0.2 68.0±0.2
Three MM46 bearing mice were treated i.v. with 10' units of
mu-IFN-y and 3 h later i.v. with 4 x 109 cells ofBPV per mouse. Two
hours later sera and tumours were resected for measurement ofTNF
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Acute toxicity ofBPV and OK-432
Groups of five males C3H/He mice (25-27 g) received an
intravenous injection of different amounts of BPV (3.5 x 10'0
to 8.5 x 1010 cells per mouse) or OK-432 (4.0 x 108 to
8.0 x 108 cells per mouse). On day 7 after the injection the
50%' lethal dose (LD50) was calculated by the method of
Behren and Karber (1935). The LD50 values for BPV and
OK-432 were 6.8 x 10'0 cells per mouse (2.6 x 1012 cells kg-')
and 5.0 x 108 cells per mouse (1.9 x 10'0 cells kg-'), respec-
tively. In this paper, biological activities were measured fol-
lowing doses of 4 x 109 cells per mouse (1.5 x 10" cells kg-')
of BPV and 3 x 108 cells per mouse (1.2 x 10'0 cells kg-') of
OK-432.
Discussion
We previously reported that endogenous TNF activity was
induced by a combination of various commercially available
drugs as a primer and a trigger. That is to say, purified
protein derivative (PPD) (Satoh et al., 1986a), immune com-
plex (Satoh et al., 1986b), macrophage activating factor
(Minagawa et al., 1988), interferon-a, P, y and interleukin-2
(Satoh et al., 1986c) were used as the primer, and OK-432
(Satoh et al., 1986c), Cholera vaccine (Minagawa et al., 1987)
and BPV (Minagawa et al., 1988) were used as the trigger.
We reported earlier (Minagawa et al., 1988) that intra-
tumoral TNF activity was induced by a local BPV injection
without a primer, and this resulted in a therapeutic effect.
In this paper, we have shown for the first time that high
intratumoral TNF activity can be induced endogenously even
by a systemic injection of BPV without primer (Figure 1,
Tables I-III). One or two hours after i.v. injection of BPV to
tumour-bearing mice, high intratumoral TNF activity was
induced, whereas activity was not detected when OK-432 was
used (Figure 1, Tables I and II). This TNF-inducing pattern
was observed in 3 different tumour cell lines. Since TNF-
accumulation in the tumour sites can affect the therapeutic
effect, high intratumoral TNF activity (as observed in Table
I), especially following systemic treatment (as in Table II),
augers well for therapeutic experiments.
Takahashi et al. (1988) reported that a cytotoxic factor
was induced intratumorally by the i.v. injection of high doses
(2 mg per mouse) of a mannoglucan prepared from Micro-
ellobosporia grisea: by the cytotoxic factor could not be
induced in mice bearing Lewis lung carcinoma. Therefore,
BPV may show a broader spectrum of TNF against a greater
number of tumour species than this mannoglucan.
The test of neutralisation by anti-MuTNF-x Ab suggests
that TNF activity assayed on L-929 cells in this paper would
be that of TNF-m-type (Table III).
TNF is thought to be released by migrating macrophages
at the tumour site because TNF activity induced in tumour
tissues by BPV is inhibited by anti-macrophage Ab (Table
IV). It seems that the tissues have been already primed,
because preliminary activation by IFN-y is not necessary for
them to induce TNF (Table V). This suggests that BPV can
be effective by a single injection, and be adaptable for clinical
use.
Antitumour therapeutic effect was found to correlate with
the intratumoral TNF induction by i.v. injection of inducers
(Figures 1-3). We therefore believe that intratumoral TNF
activity is a good predictor of therapeutic effect.
The authors acknowledge the excellent technical assistance of Yuko
Tokutake.
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